Endometrial SPOREs
Endometrial cancer starts in the cells of the inner lining of the uterus (the endometium) and is the most common type of cancer in the uterus. Endometrial cancer is typically diagnosed in women aged 45-74, and approximately 66,570 new cases and 12,940 deaths are estimated in the United States in 2021. The first Endometrial SPORE was funded in 2003, and the currently funded Endometrial SPORE at MD Anderson supports four projects focused on developing therapeutic strategies for advanced/recurrent endometrial cancer and aggressive subtypes, addressing unmet clinical needs in prevention and conservative therapy of high-risk precancerous lesions and low grade endometrial cancer, and incorporation of molecular diagnostics into clinical decision-making.